Compare ULY & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ULY | PPBT |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 6.5M |
| IPO Year | N/A | N/A |
| Metric | ULY | PPBT |
|---|---|---|
| Price | $2.46 | $0.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 104.4K |
| Earning Date | 03-11-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $127,932,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.74 | $0.53 |
| 52 Week High | $17.99 | $3.86 |
| Indicator | ULY | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 46.97 |
| Support Level | $2.12 | $0.58 |
| Resistance Level | $2.75 | $0.73 |
| Average True Range (ATR) | 0.35 | 0.04 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 15.13 | 60.59 |
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.